Toby Maher, Royal Brompton Hospital, London, met with us at ERS 2019 in Madrid to discuss the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD).
1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05)
2. What is the current standard of care for patients with progressive fibrosing uILD? (0:44)
3. Could you tell us a little about the design and findings of the recent study investigating pirfenidone in patients with progressive fibrosing uILD? (1:11)
4. Which patients are most likely to respond to this treatment approach? (1:55)
5. What further studies are planned? (2:33)
Speaker disclosures: Toby Maher has received consultancy fees, travel expenses and honoraria from Roche and Boehringer Ingelheim.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
Share this Video
Related Videos In Interstitial Lung Disease
Elisabeth Bendstrup, ERS 2021: Challenges and Advances in ILD
We were delighted to talk with Professor Elisabeth Bendstrup (Aarhus University Hospital, Denmark) around the barriers and latest advances in treating interstitial lung disease. Questions What are the barriers to the early diagnosis of interstitial lung disease (ILD)? (0:18) What are the hot topics and latest research you are looking forward to exploring in ILD […]
Elisabeth Bendstrup, ERS 2021: The STARLINER Study
Professor Elisabeth Bendstrup (Aarhus University Hospital, Denmark) spoke with touchRESPIRATORY around the STARLINER study, assessing disease behaviour in ILD and the challenges associated with home-based assessments. The abstract ‘STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results.’ (Presentation ID: 1207) was presented at ERS International Congress 2021, 5-8 […]
Lauren Troy, ERS 2019 – Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis
We met with Lauren Troy, from Royal Prince Alfred Hospital, Sydney, Australia at ERS 2019 in Madrid to discuss result of the COLDICE study into transbronchial lung cryobiopsy for interstitial lung disease diagnosis. Questions 1. In what clinical situation is a lung biopsy required to confirm a diagnosis of interstitial lung disease? (0:05) 2. What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!